Viemed Healthcare (NASDAQ:VMD) President Michael Moore Sells 31,570 Shares

Viemed Healthcare, Inc. (NASDAQ:VMD) President Michael Moore sold 31,570 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $9.42, for a total value of $297,389.40. Following the completion of the transaction, the president directly owned 1,691,044 shares in the company, valued at $15,929,634.48. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Moore also recently made the following trade(s):

• On Friday, March 20th, Michael Moore sold 65,000 shares of Viemed Healthcare stock. The stock was sold at an average price of $8.77, for a total value of $570,050.00.
• On Thursday, March 19th, Michael Moore sold 40,232 shares of Viemed Healthcare stock. The stock was sold at an average price of $9.21, for a total value of $370,536.72.

Viemed Healthcare Price Performance

VMD stock opened at $8.71 on Friday. The firm has a market cap of $336.23 million, a P/E ratio of 23.54 and a beta of 1.23. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.06 and a current ratio of 1.18. Viemed Healthcare, Inc. has a 1 year low of $5.93 and a 1 year high of $10.06. The stock has a 50-day simple moving average of $8.30 and a 200-day simple moving average of $7.37.

Viemed Healthcare (NASDAQ:VMD) last released its quarterly earnings results on Wednesday, March 4th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. The firm had revenue of $76.18 million for the quarter, compared to analyst estimates of $77.70 million. Viemed Healthcare had a return on equity of 10.72% and a net margin of 5.53%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VMD. Wall Street Zen upgraded shares of Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Zacks Research raised shares of Viemed Healthcare to a “hold” rating in a research note on Thursday, January 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Viemed Healthcare in a report on Monday, December 29th. Two research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Institutional Trading of Viemed Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of VMD. Forager Capital Management LLC lifted its position in shares of Viemed Healthcare by 12.1% in the 2nd quarter. Forager Capital Management LLC now owns 2,136,472 shares of the company’s stock worth $14,763,000 after buying an additional 230,670 shares during the last quarter. Wasatch Advisors LP boosted its holdings in shares of Viemed Healthcare by 18.4% in the 2nd quarter. Wasatch Advisors LP now owns 1,546,010 shares of the company’s stock valued at $10,683,000 after buying an additional 240,346 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Viemed Healthcare by 3.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,447,033 shares of the company’s stock valued at $10,751,000 after buying an additional 49,962 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Viemed Healthcare by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 798,515 shares of the company’s stock valued at $5,519,000 after buying an additional 15,353 shares during the last quarter. Finally, State Street Corp raised its stake in Viemed Healthcare by 1.7% during the fourth quarter. State Street Corp now owns 675,190 shares of the company’s stock worth $5,017,000 after acquiring an additional 11,385 shares during the period. 74.24% of the stock is owned by institutional investors and hedge funds.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.